[Post-COVID syndrome with fatigue and exercise intolerance: myalgic encephalomyelitis/chronic fatigue syndrome].
Renz-Polster, Herbert, Scheibenbogen, Carmen · Innere Medizin (Heidelberg, Germany) · 2022 · DOI
Quick Summary
This article explains that ME/CFS is a serious neurological and immune system disease, often triggered by infections like COVID-19, characterized by extreme fatigue lasting at least 6 months and a unique symptom called post-exertional malaise (PEM)—where even mild activity causes symptoms to worsen hours or days later. The authors stress that ME/CFS is a distinct medical condition that should not be confused with ordinary tiredness, and while there is no cure yet, treatment focuses on managing symptoms, addressing related circulation problems, and helping patients conserve energy through pacing.
Why It Matters
With post-COVID syndrome cases substantially overlapping with ME/CFS diagnostic criteria, this editorial's emphasis on recognizing ME/CFS as a distinct neurobiological entity rather than psychological fatigue is critical for appropriate patient management and preventing harmful interventions. The projected doubling of ME/CFS cases underscores urgent clinical and research needs for better diagnostic protocols and therapeutic approaches.
Observed Findings
- ME/CFS is characterized by fatigue persisting at least 6 months
- Post-exertional malaise involves symptom worsening after mild exertion, typically beginning hours to days after activity and lasting ≥14 hours
- Patients report pain, sleep disturbance, and cognitive dysfunction (thinking and memory problems)
- Circulatory, endocrine, and immune system dysregulation occur in ME/CFS patients
- A substantial proportion of post-COVID syndrome cases meet diagnostic criteria for ME/CFS
Inferred Conclusions
- ME/CFS should be recognized as a distinct neuro-immunological disease rather than non-specific chronic fatigue
- Post-COVID syndrome is expected to significantly increase prevalence of ME/CFS in coming years
- Diagnosis requires careful stepwise evaluation using international diagnostic criteria to exclude other conditions
- Current treatment is symptomatic and supportive rather than curative, emphasizing energy management and addressing associated orthostatic intolerance
Remaining Questions
- What are the specific biological mechanisms triggering and perpetuating neuro-immune dysfunction in ME/CFS?
- What evidence-based interventions most effectively manage post-exertional malaise and improve functional outcomes?
- How can post-COVID cases with ME/CFS be differentiated from other post-COVID phenotypes to enable tailored treatment approaches?
- What factors determine whether infection-induced ME/CFS will resolve or persist lifelong in individual patients?
What This Study Does Not Prove
This editorial does not present new empirical research or provide evidence supporting specific treatments; it is a clinical perspective and literature synthesis. It does not establish causal mechanisms underlying ME/CFS pathophysiology or prove efficacy of any particular pacing or symptom management strategies. It reflects current consensus but does not provide the mechanistic or intervention data needed to develop disease-modifying therapies.
Topics
Tags
Metadata
- DOI
- 10.1007/s00108-022-01369-x
- PMID
- 35925074
- Review status
- Editor reviewed
- Evidence level
- Early hypothesis, preprint, editorial, or weak support
- Last updated
- 7 April 2026